
zzso is a zzso I zzso zzso zzso zzso This phase I study determined the maximum tolerated dose zzso of two dosing schedules zzso 21 days of a zzso period zzso and continuous zzso dosing zzso zzso and zzso profiles, and preliminary zzso 

Patients with zzso advanced solid zzso were treated with zzso using a 3 + 3 zzso zzso parameters were determined after single and repeated zzso zzso effects were evaluated in zzso hair sheath cells, and skin and tumor zzso 

zzso patients were zzso The zzso of both schedules was 600 zzso zzso zzso were zzso rash and hypersensitivity zzso The most frequent drug-related adverse events included zzso zzso zzso zzso and decreased zzso Plasma zzso showed a median time to maximum concentration of 8 to 22 hours, mean terminal elimination zzso of 70 to 88 hours, and zzso to zzso zzso after daily dosing zzso zzso zzso concentration was reached between days 15 and 21, and exposure was zzso with doses up to 400 zzso zzso inhibited the zzso zzso zzso reduction in zzso of zzso zzso zzso and zzso in tumor and surrogate zzso and, unexpectedly, also inhibited the zzso zzso A partial response was seen in one patient with advanced zzso cell lung zzso Eight patients were zzso at 6 zzso zzso and clinical activity were observed irrespective of tumor zzso zzso molecular zzso 

zzso was tolerable at doses associated with zzso zzso zzso The recommended phase II dose of the capsule zzso is 600 zzso administered orally with zzso 

